RNA Disease Diagnostics (RNADD) appointed John Erickson, Jr. to the newly created position of president to lead day-to-day operations. He will report directly to company co-founder and executive chairman, Allan Oberman.
In an executive management career spanning more than three decades, Mr. Erickson has worked with healthcare, life science and clinical diagnostics businesses ranging from venture capital backed start-ups to Fortune 50 companies, building out global commercial capabilities, leading marketing and sales teams, delivering operational excellence and profitable growth, while cultivating strong thought leader relationships across multiple specialties.
Mr. Erickson joins closely-held RNADD from his management and strategy consulting firm, Erickson Healthcare Consulting. Previously, he held C-suite and senior executive leadership positions with RapidBio Systems, Johnson & Johnson’s LifeScan, Abbott Laboratories, ITC-Nexus Dx, and Bio-Rad Laboratories. In those roles, he played a key role in the development and commercialization of more than 36 products, which have generated cumulative sales in excess of $4-billion.
In a statement, Mr. Oberman said Mr. Erickson’s extensive record of accomplishment in helping to commercialize new diagnostics technologies in particular will be a great asset for RNADD going forward.
“John is exceptionally qualified to help us maximize the development and commercialization of our Antisense RNA diagnostic platform across multiple diseases,” Mr. Oberman added.
RNADD’s first product candidate is an Antisense COVID-19 molecular diagnostics test with accuracy, sensitivity, and specificity that is comparable to the gold standard RT-PCR lab diagnostic, but can be administered and read in less than five minutes at the point-of-care.